×

Actavis, Allergan are a 'strategic fit'

11:40 AM ET Mon, 17 Nov 2014

Áine Slowey, senior analyst at Datamonitor Healthcare, discusses Actavis' decision to buy Allergan for $65.5 billion, saying that Actavis has demonstrated a "strong commitment" to R&D.